不同部位胆道恶性梗阻介入治疗技术探讨和疗效评价
|
摘要
目的:恶性梗阻性黄疸是临床上较常见的疾病,大多数在诊断时已经丧失手术根治的机会,外科胆肠吻合手术创伤大。经皮经肝胆道引流管引流或内支架置入引流,已成为不能外科手术切除的癌性梗阻性黄疸的主要治疗方法之一,其疗效确切,创伤小,并发症少。在本研究旨在探讨不同部位胆道梗阻的介入治疗操作技巧,并随访观察经皮经肝胆道引流不同部位恶性梗阻性黄疸的治疗效果,探讨和分析影响生存时间的相关因素。
方法:恶性梗阻性黄疸患者83例,术前均行彩色B超检查,并详细阅读CT或常规、凝血时间、肝功等检查。包括①肝门部梗阻33例,②肝总管梗阻15例,③胆总管梗阻35例。针对不同部位的梗阻分别采用引流管植入外引流、内外引流;内支架植入:单支架植入;“Y”型双支架植入,“T”型双支架植入等方式引流。术后观察给予抗感染、保肝、抗肿瘤及对症治疗,复查B超,肝功等指标,并对其中55例通过门诊及电话随访0.4-28月,运用Kaplan-Meier乘积限法计算生存时间及生存曲线。比较不同部位胆道梗阻患者的近期疗效和生存时间。另外还对一些临床常见的因素对生存时间的影响进行了分析。
结果:83例经皮经肝胆管穿刺操作全部成功,成功率100%。其中5例行单纯外引流,9例行内外引流,78例行支架植入。术后一周平均血清总胆红素由术前的327.90±170.24μmol/L下降为172.45±137.46μmol/L(P＜0.001)。55例得到随访,随访率66.3%。总体有效率为89.16%(74/83),平均生存时间10.32±1.38月;肝门部梗阻患者近期有效率为84.85%(28/33),显效率为30.30%(10/33),平均生存时间9.59±1.80月;肝总管梗阻患者的近期有效率为86.67%(13/15),显效率为66.67%(10/15),平均生存时间5.46±1.60月;胆总管梗阻患者的近期有效率为94.30%(33/35),显效率为60%(21/35),平均生存时间12.64±2.44月。并发症发生率15.66%(13/83),30天内死亡率6.02%(5/83)。当总胆红素水平在341μmol/L以下、血清白蛋白水平在31g/L以上、血红蛋白在95g/L以上时,患者生存时间较长,预后较好。
结论:
(1)经皮经肝胆道引流术是治疗恶性梗阻性黄疸的一种有效姑息方法。能有效的缓解临床症状,减轻黄疸。因此对于恶性梗阻性黄疸患者应尽可能在早期行经皮经肝穿刺引流术,最大限度改善患者生活质量。
(2)针对梗阻部位的不同,可采用经皮经肝单支架植入,“Y”型或“T”型支架植入。手术成功率高,易于推广应用。
(3)术前胆红素水平,血清白蛋白水平和血红蛋白水平是术后生存时间的相关因素,可以用来初步预测患者的预后,可以为手术时机及引流管或内支架植入的选择提供参考。
Objective: Malignant obstructive jaundice is a commen disease clinically, and when diagnose ,most of the patients have lost the opportunity of operative eradication, which causing sever trauma , high mortality and short life span after operation. PTCD have become one of the main therapeutic method of malignant obstructive jaundice which have lost operative opportunity. They have certain curative effect, small trauma and little complication. This study aim at discussing operative skill of interventional therapy in different location of obstruction and following up the curative effect of different therapy of PTCD, to probe into and analyze the correlative factor which affect the curative effect in short time and life span.
Methods: 83 patients of malignant bile duct obstruction were included in this study, including: 35 cases of common bile duct obstruction, 15 cases of common hepatic duct obstruction, and 33 cases of hilar obstruction. They were treated with different therapy of PTCD, according to the different type of bile duct obstruction. The lately curative effect observed. And then 55 (66.3%) of them were followed up by 0.4-28 months and were observed survival time. We analyze different of survival time between the different location of biliary obstruction and different therapy types of PTBD. In addition we analyze the affect of other common factors to the survival time.
Results: In my study, all of the 83 patients cases were treated technological successful (100%), and stents were placed in 78 cases, external drainage in 5 cases and internal /external drainage tube in 9 cases. Their clinical symptom are better than that before operation. The serllm total bilirubin decreased from 327.90±170.24μmol/L to 172.45±137.46μmol/L one week after the procedure(P<0.001). The lately clinical effective rate is 89.16% (74/83), and the mean survival time is 10.32±1.38 months. The clinical outcome of three different types of bile duct obstruction is like this: 1) common bile duct obstruction, with a lately clinical effective rate of 94.30% (33/35), and the mean survival time of 12.64±2.44 months. 2) common hepatic duct obstruction with a lately clinical effective rate of 86.67% (13/15), and the mean survival time of 5.46±1.60 months. 3) hilar obstruction with a lately clinical effective rate of 84.85% (28/33), and the mean survival time of 9.59±1.80months. 15 cases of common hepatic duct obstruction, and 33 cases of hilar obstruction. Five cases died within 1 month (6.02%) after operate. Complications occurred in 13 cases (15.66%). The value of preoperative serum total bilirubin, albumin and hemoglobin is the relatedfactors influencing survival time.
Conclusion:
(1) PTCD is an effective palliative method of therapy in malignant obstructive jaundice. It can release the clinical symptom and alleviate Jaundic effectually, hence the patients should receive PTCD in the early time to improve the life quality maximumly.
(2) The therapy of PTCD should be chosen, according to the different type of bile duct obstruction.
(3) The value of preoperative serum total bilirubin, albumin and hemoglobin is the related factors influencing survival time.And they can forecast the prognosis initially and provide consult for the choice of operative way.
方法:恶性梗阻性黄疸患者83例,术前均行彩色B超检查,并详细阅读CT或常规、凝血时间、肝功等检查。包括①肝门部梗阻33例,②肝总管梗阻15例,③胆总管梗阻35例。针对不同部位的梗阻分别采用引流管植入外引流、内外引流;内支架植入:单支架植入;“Y”型双支架植入,“T”型双支架植入等方式引流。术后观察给予抗感染、保肝、抗肿瘤及对症治疗,复查B超,肝功等指标,并对其中55例通过门诊及电话随访0.4-28月,运用Kaplan-Meier乘积限法计算生存时间及生存曲线。比较不同部位胆道梗阻患者的近期疗效和生存时间。另外还对一些临床常见的因素对生存时间的影响进行了分析。
结果:83例经皮经肝胆管穿刺操作全部成功,成功率100%。其中5例行单纯外引流,9例行内外引流,78例行支架植入。术后一周平均血清总胆红素由术前的327.90±170.24μmol/L下降为172.45±137.46μmol/L(P＜0.001)。55例得到随访,随访率66.3%。总体有效率为89.16%(74/83),平均生存时间10.32±1.38月;肝门部梗阻患者近期有效率为84.85%(28/33),显效率为30.30%(10/33),平均生存时间9.59±1.80月;肝总管梗阻患者的近期有效率为86.67%(13/15),显效率为66.67%(10/15),平均生存时间5.46±1.60月;胆总管梗阻患者的近期有效率为94.30%(33/35),显效率为60%(21/35),平均生存时间12.64±2.44月。并发症发生率15.66%(13/83),30天内死亡率6.02%(5/83)。当总胆红素水平在341μmol/L以下、血清白蛋白水平在31g/L以上、血红蛋白在95g/L以上时,患者生存时间较长,预后较好。
结论:
(1)经皮经肝胆道引流术是治疗恶性梗阻性黄疸的一种有效姑息方法。能有效的缓解临床症状,减轻黄疸。因此对于恶性梗阻性黄疸患者应尽可能在早期行经皮经肝穿刺引流术,最大限度改善患者生活质量。
(2)针对梗阻部位的不同,可采用经皮经肝单支架植入,“Y”型或“T”型支架植入。手术成功率高,易于推广应用。
(3)术前胆红素水平,血清白蛋白水平和血红蛋白水平是术后生存时间的相关因素,可以用来初步预测患者的预后,可以为手术时机及引流管或内支架植入的选择提供参考。
Objective: Malignant obstructive jaundice is a commen disease clinically, and when diagnose ,most of the patients have lost the opportunity of operative eradication, which causing sever trauma , high mortality and short life span after operation. PTCD have become one of the main therapeutic method of malignant obstructive jaundice which have lost operative opportunity. They have certain curative effect, small trauma and little complication. This study aim at discussing operative skill of interventional therapy in different location of obstruction and following up the curative effect of different therapy of PTCD, to probe into and analyze the correlative factor which affect the curative effect in short time and life span.
Methods: 83 patients of malignant bile duct obstruction were included in this study, including: 35 cases of common bile duct obstruction, 15 cases of common hepatic duct obstruction, and 33 cases of hilar obstruction. They were treated with different therapy of PTCD, according to the different type of bile duct obstruction. The lately curative effect observed. And then 55 (66.3%) of them were followed up by 0.4-28 months and were observed survival time. We analyze different of survival time between the different location of biliary obstruction and different therapy types of PTBD. In addition we analyze the affect of other common factors to the survival time.
Results: In my study, all of the 83 patients cases were treated technological successful (100%), and stents were placed in 78 cases, external drainage in 5 cases and internal /external drainage tube in 9 cases. Their clinical symptom are better than that before operation. The serllm total bilirubin decreased from 327.90±170.24μmol/L to 172.45±137.46μmol/L one week after the procedure(P<0.001). The lately clinical effective rate is 89.16% (74/83), and the mean survival time is 10.32±1.38 months. The clinical outcome of three different types of bile duct obstruction is like this: 1) common bile duct obstruction, with a lately clinical effective rate of 94.30% (33/35), and the mean survival time of 12.64±2.44 months. 2) common hepatic duct obstruction with a lately clinical effective rate of 86.67% (13/15), and the mean survival time of 5.46±1.60 months. 3) hilar obstruction with a lately clinical effective rate of 84.85% (28/33), and the mean survival time of 9.59±1.80months. 15 cases of common hepatic duct obstruction, and 33 cases of hilar obstruction. Five cases died within 1 month (6.02%) after operate. Complications occurred in 13 cases (15.66%). The value of preoperative serum total bilirubin, albumin and hemoglobin is the relatedfactors influencing survival time.
Conclusion:
(1) PTCD is an effective palliative method of therapy in malignant obstructive jaundice. It can release the clinical symptom and alleviate Jaundic effectually, hence the patients should receive PTCD in the early time to improve the life quality maximumly.
(2) The therapy of PTCD should be chosen, according to the different type of bile duct obstruction.
(3) The value of preoperative serum total bilirubin, albumin and hemoglobin is the related factors influencing survival time.And they can forecast the prognosis initially and provide consult for the choice of operative way.
引文
[1]Henson DE,Albores-Saavedra J,Corle D.Carcinoma of the extrahepatic bile duct:Histologic types,stage of disease,grade,and survival rates[J].Cancer,1992,70(6):1948 - 1501.
[2]Bismuth H,Castaing D,Traynor O.Resection or palliation:Priority of surgery in the treatment of hilar cancer[J].World J Surg,1988,12(1):39-47.
[3]Ballinger AB,McHugh M,Catnach SM,et al.Symptom relief and quality of life after stenting for malignant bile duct obstruction.Gut.1994;35:467-470.
[4]Lameris JS,Stroker J,Nijs HG,et al.Malignant biliary obs-truction;percutaneous use of self-expendable stent[see comments].Ridiology,1991,179:703.
[5]van Milligen de Wit AW,et.Lack of complications followingshrot-term stent therapy for extrahepatic bile duct strictures in primary sclerosingcholangitis.Gastointest Endoscopy,1997Oct;46(4):344-347.
[6]Doctor N,Dick R,Rai R,et al.Results of percutaneous plastic stents for malignant distal biliary obstruction following failed endoscopicstent insertion and comparison with current literature on expandable metallic stents.Eur J Gastroenterol Hepatol,1999July;11(7):775-780.
[7]Molnar,W.and A.E.Stockum,Relief of obstructive jaundice through percutaneous transhepatic catheter-a new therapeutic method.Am J Roentgenol Radium Ther Nucl Med,1974.122(2):p.356-67.
[8]Covey,A.M.and K.T.Brown,Palliative percutaneous drainage in malignant biliary obstruction.Part 2:Mechanisms and postprocedure management.J Support Oncol,2006.4(7):p.329-35.
[9]韩新巍,李臻.胆管癌并阻塞性黄疸的影像学诊断及介入治疗现状与进展.世界华人消化杂志 2008:16(29):3249-3254.
[10]nal,M.Aksungur,E.Akgu|¨l,E.et al.Percutaneous Placement of Metallic Stents in Malignant Biliary Obstruction:One-Stage or Two-Stage Procedure? Pre-Dilate or Not? Cardiovasc Intervent Radiol(2003) 26:40-45.
[11]宛新建,郑萍,王兴鹏,万荣,周如茵,王娜,茅柳水.金属和塑料支架 置入治疗胰头癌伴阻塞性黄疸的疗效分析.胰腺病学 2007;7:285-287.
[12]Lee,D.H.,et al.,Percutaneous placement of self-expandable metallic biliary stents in malignant extrahepatic strictures:indications of transpapillary and suprapapillary methods.Korean J Radiol,2000.1(2):p.65-72.
[13]Hatzidakis,A.A.,et al.,Nitinol stents for palliative treatmem of malignant obstructive jaundice:should we stent the sphincter of Oddi in every case? Cardiovasc Intervem Radiol,2001.24(4):p.245-8.
[14]李红,郝萍,韩德义.高位恶性胆道梗阻多支架植入术的临床应用及疗效分析.中华肝胆外科杂志,2005 11:173-175.
[15]Inal M,Akgnl E,Aksungnr E,et al.Percutaneous placemem of biliary metallic stems in patients with malign ant hilar obstruction:unilobar versus bilobar drainage.J Vasc Interv Radiol,2003,14:1409-1416.
[16]Khan SA,Davidson BR,Goldin,R,et al.Guidelines for the diagnosis and treatment of cholangiocarcinoma:consensus document.Gut,2002,51:1-9.
[17]谢宗贵,李新民,金鹏,谢志勇,易玉海,张绪平.单通道双支架植入技术治疗肝门部胆管癌.介入放射学杂志 2003:12:436-438.
[18]翟仁友,戴定可,王剑峰,等.高位胆管梗阻的介入治疗和近期疗效分析.介入放射学杂志,2006 15:491-493.
[19]Covey,A.M.and K.T.Brown,Palliative percutaneous drainage in malignant biliary obstruction.Part 1:indications and preprocedure evaluation.J Support Oncol,2006.4(6):p.269-73.
[20]van Delden,O.M.and J.S.Lameris,Percutaneous drainage and stenting for palliation of malignant bile duct obstruction.Eur Radiol,2008.18(3):p.448-56.
[21]程庆保,张柏和,张永杰等肝门部胆管癌预后因素肿瘤 2005,25(2):166-169.
[22]Cheng Hsi Su,Shyh Haw Tsay,Cheng Chung Wu,et al.Factors influencing postoperative morbidity,mortality and survival after resection for hilar cholangiocarcinoma.Hepato-biliary Pancreat Surg,2000,7(2):128-134.
[1]Henson DE,Albores-Saavedra J,Corle D.Carcinoma of the extrahepatic bile duct:Histologic types,stage of disease,grade,and survival rates[J].Cancer,1992,70(6):1948 - 1501.
[2]Bismuth H,Castaing D,Traynor O.Resection or palliation:Priority of surgery in the treatment of hilar cancer[J].World J Surg,1988,12(1):39-47.
[3]单鸿,罗鹏飞,李彦豪.临床介入治疗学[M].广州:广东科技出版社,1997.23-24.
[4]Molnar,W.and A.E.Stockum,Relief of obstructive jaundice through percutaneous transhepatic catheter--a new therapeutic method.Am J Roentgenol Radium Ther Nucl Med,1974.122(2):p.356-67.
[5]Hii MW,Gibson RN.Role of radiology in the treatment of malignant hilar biliary strictures 1:review of the literature.Zentralbl Chir.2003 Nov;128(11):936-943.
[6]曹绣虎,邓秉枢,万德森,等.肝外胆管癌.中华外科杂志,1984,22:164.
[7]梁立华,陈立雄“枯树征”、“软藤征”在梗阻性黄疽中的诊断价值。临床肝胆病杂志,1995:11(2):102-103.
[8]方昆豪.等.恶性梗阻性黄疽的影像学表现与治疗.癌症,1988:7:197.
[9]李明科.经皮肝穿刺胆道造影对恶性梗阻性黄疽病因诊断价值的探讨.肿瘤,1994:14(3)159.
[10]Tsai CC,Mo LR,Chou CY,et al.Percutaneous transhepatic transluminal forceps biopsy in obstructive jaundice.Hepatogastroenterology,1997,44:770]
[11]Jung GS,Huh JD,Lee SU,et al.Bile duct:analysi s of percutaneous transluminal forceps biopsy in 130 patients suspected of having malignant biliary obstruction.Radiology,2002,224:725.
[12]韩新巍,李永东,高雪梅,等.经皮肝穿胆道造影术下胆管活检的临床研究.介入放射学杂志,2002,11:351.
[13]Jung GS,Huh JD,Lee SU,et al.Bile duct:analysi s of percutaneous transluminal forceps biopsy in 130 patients suspected of having malignant biliary obstruction.Radiology,2002,224:725.
[14]Covey,A.M.and K.T.Brown,Palliative percutaneous drainage in malignant biliary obstruction.Part 2:Mechanisms and postprocedure management.J Support Oncol,2006.4(7):p.329-35.
[15]王高仁,鞠永健,丁文彬,金杰,杨劲松.经皮肝穿刺胆道内支架引流术治疗恶性阻塞性黄疸21例疗效分析.中国癌症杂志 2006;16:511-512。
[16]吴安乐,颜志平,王建华,罗剑钧,程洁敏,钱晟,王小林,刘清欣,龚高全,刘清欣,钱晟,罗剑钧.恶性梗阻性黄疸的微创法引流.临床放射学杂志 2002;21:448-451。
[17]陈晓明,陆骊工,李勇,胡宝山,罗鹏飞.完全型恶性阻塞性黄疸胆管再通的方法探讨.临床放射学杂志 2006:25:1051-1054.
[18]韩新巍.阻塞性黄疸介入诊断与治疗操作规范讨论.介入放射学杂志 2002;11:393-396.
[19]nal,M.Aksungur,E.Akgu|¨l,E.et al.Percutaneous Placement of Metallic Stents in Malignant Biliary Obstruction:One-Stage or Two-Stage Procedure? Pre-Dilate or Not? Cardiovasc Intervent Radiol(2003) 26:40-45.
[20]宛新建,郑萍,王兴鹏,万荣,周如茵,王娜,茅柳水.金属和塑料支架置入治疗胰头癌伴阻塞性黄疸的疗效分析.胰腺病学 2007;7:285-287.
[21]韩新巍,李臻.胆管癌并阻塞性黄疸的影像学诊断及介入治疗现状与进展.世界华人消化杂志 2008;16(29):3249-3254.
[22]Chiou YY,Tseng HS,Chiang JH,Hwang JI,Chou YH,Chang CY.Percutaneous placement of metallic stents in the management of malignant biliary obstruction.J Formos Med Assoc 2005;104:738-743.
[23]Lee,D.H.,et al.,Percutaneous placement of self-expandable metallic biliary stents in malignant extrahepatic strictures:indications of transpapillary and suprapapillary methods.Korean J Radiol,2000.1(2):p.65-72.
[24]Hatzidakis,A.A.,et al.,Nitinol stents for palliative treatment of malignant obstructive jaundice:should we stent the sphincter of Oddi in every case? Cardiovasc Intervent Radiol,2001.24(4):p.245-8.
[25]Covey,A.M.and K.T.Brown,Palliative percutaneous drainage in malignant biliary obstruction.Part 2:Mechanisms and postprocedure management.J Support Oncol,2006.4(7):p.329-35.
26.罗祖炎,陈方宏,袁建华,等.胆道双金属支架植入姑息性治疗肝门胆管癌的临床价值.介入放射学杂志,2004 13:454-456.22.
[27]Carrasco CH,Zornoza J,Bechtel WP,et al.Malignant biliary obstruction Complications of percutaneous biliary drainage.Radiology 2000 215:343-356.
28.李红,郝萍,韩德义.高位恶性胆道梗阻多支架植入术的临床应用及疗效分析.中华肝胆外科杂志,2005 11:173-175.
[29]Inal M,Akgnl E,Aksungnr E,et al.Percutaneous placement of biliary metallic stems in patients with malign ant hilar obstruction:unilobar versus bilobar drainage.J Vasc Interv Radiol,2003,14:1409-1416.
[30]Khan SA,Davidson BR,Goldin,R,et al.Guidelines for the diagnosis and treatment of cholangiocarcinoma:consensus document.Gut,2002,51:1-9.
[31]Chang WH,Kortan P,Haber GB,et al.Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage.Gastrointest Endosc.1998,47:354-362.
[32]徐克,刘瑞宝,赵仲春,等.经皮经肝单侧入路行双侧胆管内引流术的临床应用.中国医学影像技术,2003,19:1047-1049.
[33]卢再鸣,郭启勇,刘兆玉,等.金属内支架治疗复杂型肝门部胆管癌的临床应用研究.中国临床医学影像杂志,2005,16:383-386.
[34]谢宗贵,李新民,金鹏,谢志勇,易玉海,张绪平.单通道双支架植入技术治疗肝门部胆管癌.介入放射学杂志 2003;12:436-438.
[35]翟仁友,戴定可,王剑峰,等.高位胆管梗阻的介入治疗和近期疗效分析.介入放射学杂志,2006 15:491-493.
[36]Covey,A.M.and K.T.Brown,Palliative percutaneous drainage in malignant biliary obstruction.Part 1:indications and preprocedure evaluation.J Support Oncol,2006.4(6):p.269-73.
[37]曹亦军,吴坚,奉典旭,等.胆道支架植入加介入化疗方法治疗高位恶性胆道梗阻的体会.外科理论与实践,2004 9:227-229.
[38].王建华,王小林,颜志平.腹部介入放射学.上海:上海医科大学出版社, 1998:113.
[39]Herber S,Otto G,Schneider J,Manzl N,KummerI,Kanzler S,Schuchmann A,Thies J,Du|¨ber C,Pitton M.Transarterial chemoembolization(TACE) for inoperable intrahepatic cholangiocarcinoma.Cardiovasc Intervent Radiol 2007;30:1156-1165.
[40].韩新巍,李永东,马南,邢古生,马波,吴刚.胆管癌性阻塞内支架术后再狭窄的介入治疗.介入放射学杂志 2002;11:354-356.
[41]谢宗贵,张希全,李凡东,等.胆道支架技术5年回顾0213例随访报告).中华肝胆外科杂志,2002,8:595-597.
[42]Lygidakis NJ,Sgourakis GJ,Dedemadi GV,et al.Long-term results following resectional surgery for Klatskin tumours:A twenty year personal experience.Hepato Gastroenterol,2001,48:95-101.
[43]曹亦军,吴坚,奉典旭,等.胆道支架植入加介入化疗方法治疗高位恶性胆道梗阻的体会.外科理论与实践,2004 9:227-229.
[44]Song SY,Chung JW,Han JK,et al.Liver abscess after transcatheter oily chemoembolization for hepatic tumors:incidence,predisposing factors and clinical outcome.J Vasc Interv Radiol,2001,12:313-320.
[45]陈颐,王小林,颜志平,等.动脉化疗栓塞治疗恶性梗阻性黄疽.中国临床医学,2004 11:246-250.
[2]Bismuth H,Castaing D,Traynor O.Resection or palliation:Priority of surgery in the treatment of hilar cancer[J].World J Surg,1988,12(1):39-47.
[3]Ballinger AB,McHugh M,Catnach SM,et al.Symptom relief and quality of life after stenting for malignant bile duct obstruction.Gut.1994;35:467-470.
[4]Lameris JS,Stroker J,Nijs HG,et al.Malignant biliary obs-truction;percutaneous use of self-expendable stent[see comments].Ridiology,1991,179:703.
[5]van Milligen de Wit AW,et.Lack of complications followingshrot-term stent therapy for extrahepatic bile duct strictures in primary sclerosingcholangitis.Gastointest Endoscopy,1997Oct;46(4):344-347.
[6]Doctor N,Dick R,Rai R,et al.Results of percutaneous plastic stents for malignant distal biliary obstruction following failed endoscopicstent insertion and comparison with current literature on expandable metallic stents.Eur J Gastroenterol Hepatol,1999July;11(7):775-780.
[7]Molnar,W.and A.E.Stockum,Relief of obstructive jaundice through percutaneous transhepatic catheter-a new therapeutic method.Am J Roentgenol Radium Ther Nucl Med,1974.122(2):p.356-67.
[8]Covey,A.M.and K.T.Brown,Palliative percutaneous drainage in malignant biliary obstruction.Part 2:Mechanisms and postprocedure management.J Support Oncol,2006.4(7):p.329-35.
[9]韩新巍,李臻.胆管癌并阻塞性黄疸的影像学诊断及介入治疗现状与进展.世界华人消化杂志 2008:16(29):3249-3254.
[10]nal,M.Aksungur,E.Akgu|¨l,E.et al.Percutaneous Placement of Metallic Stents in Malignant Biliary Obstruction:One-Stage or Two-Stage Procedure? Pre-Dilate or Not? Cardiovasc Intervent Radiol(2003) 26:40-45.
[11]宛新建,郑萍,王兴鹏,万荣,周如茵,王娜,茅柳水.金属和塑料支架 置入治疗胰头癌伴阻塞性黄疸的疗效分析.胰腺病学 2007;7:285-287.
[12]Lee,D.H.,et al.,Percutaneous placement of self-expandable metallic biliary stents in malignant extrahepatic strictures:indications of transpapillary and suprapapillary methods.Korean J Radiol,2000.1(2):p.65-72.
[13]Hatzidakis,A.A.,et al.,Nitinol stents for palliative treatmem of malignant obstructive jaundice:should we stent the sphincter of Oddi in every case? Cardiovasc Intervem Radiol,2001.24(4):p.245-8.
[14]李红,郝萍,韩德义.高位恶性胆道梗阻多支架植入术的临床应用及疗效分析.中华肝胆外科杂志,2005 11:173-175.
[15]Inal M,Akgnl E,Aksungnr E,et al.Percutaneous placemem of biliary metallic stems in patients with malign ant hilar obstruction:unilobar versus bilobar drainage.J Vasc Interv Radiol,2003,14:1409-1416.
[16]Khan SA,Davidson BR,Goldin,R,et al.Guidelines for the diagnosis and treatment of cholangiocarcinoma:consensus document.Gut,2002,51:1-9.
[17]谢宗贵,李新民,金鹏,谢志勇,易玉海,张绪平.单通道双支架植入技术治疗肝门部胆管癌.介入放射学杂志 2003:12:436-438.
[18]翟仁友,戴定可,王剑峰,等.高位胆管梗阻的介入治疗和近期疗效分析.介入放射学杂志,2006 15:491-493.
[19]Covey,A.M.and K.T.Brown,Palliative percutaneous drainage in malignant biliary obstruction.Part 1:indications and preprocedure evaluation.J Support Oncol,2006.4(6):p.269-73.
[20]van Delden,O.M.and J.S.Lameris,Percutaneous drainage and stenting for palliation of malignant bile duct obstruction.Eur Radiol,2008.18(3):p.448-56.
[21]程庆保,张柏和,张永杰等肝门部胆管癌预后因素肿瘤 2005,25(2):166-169.
[22]Cheng Hsi Su,Shyh Haw Tsay,Cheng Chung Wu,et al.Factors influencing postoperative morbidity,mortality and survival after resection for hilar cholangiocarcinoma.Hepato-biliary Pancreat Surg,2000,7(2):128-134.
[1]Henson DE,Albores-Saavedra J,Corle D.Carcinoma of the extrahepatic bile duct:Histologic types,stage of disease,grade,and survival rates[J].Cancer,1992,70(6):1948 - 1501.
[2]Bismuth H,Castaing D,Traynor O.Resection or palliation:Priority of surgery in the treatment of hilar cancer[J].World J Surg,1988,12(1):39-47.
[3]单鸿,罗鹏飞,李彦豪.临床介入治疗学[M].广州:广东科技出版社,1997.23-24.
[4]Molnar,W.and A.E.Stockum,Relief of obstructive jaundice through percutaneous transhepatic catheter--a new therapeutic method.Am J Roentgenol Radium Ther Nucl Med,1974.122(2):p.356-67.
[5]Hii MW,Gibson RN.Role of radiology in the treatment of malignant hilar biliary strictures 1:review of the literature.Zentralbl Chir.2003 Nov;128(11):936-943.
[6]曹绣虎,邓秉枢,万德森,等.肝外胆管癌.中华外科杂志,1984,22:164.
[7]梁立华,陈立雄“枯树征”、“软藤征”在梗阻性黄疽中的诊断价值。临床肝胆病杂志,1995:11(2):102-103.
[8]方昆豪.等.恶性梗阻性黄疽的影像学表现与治疗.癌症,1988:7:197.
[9]李明科.经皮肝穿刺胆道造影对恶性梗阻性黄疽病因诊断价值的探讨.肿瘤,1994:14(3)159.
[10]Tsai CC,Mo LR,Chou CY,et al.Percutaneous transhepatic transluminal forceps biopsy in obstructive jaundice.Hepatogastroenterology,1997,44:770]
[11]Jung GS,Huh JD,Lee SU,et al.Bile duct:analysi s of percutaneous transluminal forceps biopsy in 130 patients suspected of having malignant biliary obstruction.Radiology,2002,224:725.
[12]韩新巍,李永东,高雪梅,等.经皮肝穿胆道造影术下胆管活检的临床研究.介入放射学杂志,2002,11:351.
[13]Jung GS,Huh JD,Lee SU,et al.Bile duct:analysi s of percutaneous transluminal forceps biopsy in 130 patients suspected of having malignant biliary obstruction.Radiology,2002,224:725.
[14]Covey,A.M.and K.T.Brown,Palliative percutaneous drainage in malignant biliary obstruction.Part 2:Mechanisms and postprocedure management.J Support Oncol,2006.4(7):p.329-35.
[15]王高仁,鞠永健,丁文彬,金杰,杨劲松.经皮肝穿刺胆道内支架引流术治疗恶性阻塞性黄疸21例疗效分析.中国癌症杂志 2006;16:511-512。
[16]吴安乐,颜志平,王建华,罗剑钧,程洁敏,钱晟,王小林,刘清欣,龚高全,刘清欣,钱晟,罗剑钧.恶性梗阻性黄疸的微创法引流.临床放射学杂志 2002;21:448-451。
[17]陈晓明,陆骊工,李勇,胡宝山,罗鹏飞.完全型恶性阻塞性黄疸胆管再通的方法探讨.临床放射学杂志 2006:25:1051-1054.
[18]韩新巍.阻塞性黄疸介入诊断与治疗操作规范讨论.介入放射学杂志 2002;11:393-396.
[19]nal,M.Aksungur,E.Akgu|¨l,E.et al.Percutaneous Placement of Metallic Stents in Malignant Biliary Obstruction:One-Stage or Two-Stage Procedure? Pre-Dilate or Not? Cardiovasc Intervent Radiol(2003) 26:40-45.
[20]宛新建,郑萍,王兴鹏,万荣,周如茵,王娜,茅柳水.金属和塑料支架置入治疗胰头癌伴阻塞性黄疸的疗效分析.胰腺病学 2007;7:285-287.
[21]韩新巍,李臻.胆管癌并阻塞性黄疸的影像学诊断及介入治疗现状与进展.世界华人消化杂志 2008;16(29):3249-3254.
[22]Chiou YY,Tseng HS,Chiang JH,Hwang JI,Chou YH,Chang CY.Percutaneous placement of metallic stents in the management of malignant biliary obstruction.J Formos Med Assoc 2005;104:738-743.
[23]Lee,D.H.,et al.,Percutaneous placement of self-expandable metallic biliary stents in malignant extrahepatic strictures:indications of transpapillary and suprapapillary methods.Korean J Radiol,2000.1(2):p.65-72.
[24]Hatzidakis,A.A.,et al.,Nitinol stents for palliative treatment of malignant obstructive jaundice:should we stent the sphincter of Oddi in every case? Cardiovasc Intervent Radiol,2001.24(4):p.245-8.
[25]Covey,A.M.and K.T.Brown,Palliative percutaneous drainage in malignant biliary obstruction.Part 2:Mechanisms and postprocedure management.J Support Oncol,2006.4(7):p.329-35.
26.罗祖炎,陈方宏,袁建华,等.胆道双金属支架植入姑息性治疗肝门胆管癌的临床价值.介入放射学杂志,2004 13:454-456.22.
[27]Carrasco CH,Zornoza J,Bechtel WP,et al.Malignant biliary obstruction Complications of percutaneous biliary drainage.Radiology 2000 215:343-356.
28.李红,郝萍,韩德义.高位恶性胆道梗阻多支架植入术的临床应用及疗效分析.中华肝胆外科杂志,2005 11:173-175.
[29]Inal M,Akgnl E,Aksungnr E,et al.Percutaneous placement of biliary metallic stems in patients with malign ant hilar obstruction:unilobar versus bilobar drainage.J Vasc Interv Radiol,2003,14:1409-1416.
[30]Khan SA,Davidson BR,Goldin,R,et al.Guidelines for the diagnosis and treatment of cholangiocarcinoma:consensus document.Gut,2002,51:1-9.
[31]Chang WH,Kortan P,Haber GB,et al.Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage.Gastrointest Endosc.1998,47:354-362.
[32]徐克,刘瑞宝,赵仲春,等.经皮经肝单侧入路行双侧胆管内引流术的临床应用.中国医学影像技术,2003,19:1047-1049.
[33]卢再鸣,郭启勇,刘兆玉,等.金属内支架治疗复杂型肝门部胆管癌的临床应用研究.中国临床医学影像杂志,2005,16:383-386.
[34]谢宗贵,李新民,金鹏,谢志勇,易玉海,张绪平.单通道双支架植入技术治疗肝门部胆管癌.介入放射学杂志 2003;12:436-438.
[35]翟仁友,戴定可,王剑峰,等.高位胆管梗阻的介入治疗和近期疗效分析.介入放射学杂志,2006 15:491-493.
[36]Covey,A.M.and K.T.Brown,Palliative percutaneous drainage in malignant biliary obstruction.Part 1:indications and preprocedure evaluation.J Support Oncol,2006.4(6):p.269-73.
[37]曹亦军,吴坚,奉典旭,等.胆道支架植入加介入化疗方法治疗高位恶性胆道梗阻的体会.外科理论与实践,2004 9:227-229.
[38].王建华,王小林,颜志平.腹部介入放射学.上海:上海医科大学出版社, 1998:113.
[39]Herber S,Otto G,Schneider J,Manzl N,KummerI,Kanzler S,Schuchmann A,Thies J,Du|¨ber C,Pitton M.Transarterial chemoembolization(TACE) for inoperable intrahepatic cholangiocarcinoma.Cardiovasc Intervent Radiol 2007;30:1156-1165.
[40].韩新巍,李永东,马南,邢古生,马波,吴刚.胆管癌性阻塞内支架术后再狭窄的介入治疗.介入放射学杂志 2002;11:354-356.
[41]谢宗贵,张希全,李凡东,等.胆道支架技术5年回顾0213例随访报告).中华肝胆外科杂志,2002,8:595-597.
[42]Lygidakis NJ,Sgourakis GJ,Dedemadi GV,et al.Long-term results following resectional surgery for Klatskin tumours:A twenty year personal experience.Hepato Gastroenterol,2001,48:95-101.
[43]曹亦军,吴坚,奉典旭,等.胆道支架植入加介入化疗方法治疗高位恶性胆道梗阻的体会.外科理论与实践,2004 9:227-229.
[44]Song SY,Chung JW,Han JK,et al.Liver abscess after transcatheter oily chemoembolization for hepatic tumors:incidence,predisposing factors and clinical outcome.J Vasc Interv Radiol,2001,12:313-320.
[45]陈颐,王小林,颜志平,等.动脉化疗栓塞治疗恶性梗阻性黄疽.中国临床医学,2004 11:246-250.